InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.85
(
-0.19%
)
US TECH 100
19,296.80
(
-0.19%
)
Dow Jones
42,089.67
(
0.15%
)
Brent Oil
74.22
(
-0.14%
)
Bitcoin
62,821.19
(
-0.20%
)
Post# of 253167
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120474
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 207850

Tuesday, 01/16/2018 9:30:01 AM

Tuesday, January 16, 2018 9:30:01 AM

Post# of 253167
MRK—Keytruda hit on OS/PFS in KEYNOTE-189 interim analysis:

https://www.businesswire.com/news/home/20180116005680/en/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Survival-Progression-Free

KEYNOTE-189 tested chemo ± Keytruda is first-line non-squamous NSCLC for patients with any PD-L1 status. The hazard ratio for OS/PFS and other details will be presented at an unspecified medical conference (probably ASCO).

Success in KEYNIOTE-189 allows MRK to convert the accelerated approval from the small KEYNOTE-021G study (#msg-131249474) into a full FDA approval.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up